<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5283599 Figure_1-A</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 1-A</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A</infon>
    <passage>
      <offset>0</offset>
      <text>A Scheme of the lentiviral vector with inducible FlagOmomyc (top) and immunoblotting (bottom) of FlagOmomyc and actin loading control upon Dox treatment of BT168FOcells for 0-48 hours.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_1-B</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Proliferation curves of BT168FO and BT168GFPcells upon Dox treatment for 0-96 h (n = 3; mean &#177; SD). Viable cells were counted using a haemocytometer.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_1-C-D</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 1-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>C-D Self-renewal assay upon Dox treatment. C: histograms showing the percentage of cells capable of re-forming a neurosphere seven days after dissociation (n = 3; mean &#177; SD). D: representative micrographs of BT168FO cell neurospheres.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_1-E</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 1-E</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E</infon>
    <passage>
      <offset>0</offset>
      <text>E qRT-PCR of proliferation, stem cell and differentiation markers (CCND1, PTEN, SOX2, NOTCH1, NESTIN, MYC) in BT168FO cells after 48 h Dox treatment, compared to uninduced cells (n = 3; mean &#177; SD). Expression levels in non-induced cells were set as 1.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_1-F</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 1-F</infon>
    <infon key="sourcedata_figure_dir">Figure_1-F</infon>
    <passage>
      <offset>0</offset>
      <text>F. Transwell migration assay of BT168FO cells after 3 days with or without Dox (n = 3; mean &#177; SD). 10 fields were counted per assay.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_1-G</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 1-G</infon>
    <infon key="sourcedata_figure_dir">Figure_1-G</infon>
    <passage>
      <offset>0</offset>
      <text>G. Immunofluorescence analyses of GSC differentiation. To stimulate differentiation BT168FO were grown as monolayer in the presence of serum and treated with doxycycline for up to 7 days. The upper panel displays immunofluorescence images of NESTIN, GFAP, &#223;-tubulin III, SOX2, and FlagOmomyc expression. FlagOmomyc blunted SOX2 expression and decreased GFAP and NESTIN protein levels, while inducing the onset of &#223;-tubulin III. The lower panel shows the percentage of positive cells for each cell marker evaluated (n = 4; mean &#177; SD). 16 fields for each assay were examined; scale bar = 100 &#956;m.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_2-A-H</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 2-A-H</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A-H</infon>
    <passage>
      <offset>0</offset>
      <text>A-H Immunostaining of representative xenografts derived from na&#239;ve (control) and Omomyc expressing BT168FO cells. A-D) Flag, Ki67, CD31, and DCX (doublecortin) immunostaining of adjacent sections in control and Omomyc xenografts. E-G) Differentiation phenotype investigated by GFAP, &#223;-tubulin III, and OLIG2 staining. H) Immunostaining for anti-human nuclei. Representative images are shown. Scale bar = 100&#956;m.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_3-A</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 3-A</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A</infon>
    <passage>
      <offset>0</offset>
      <text>A-B Seqminer heatmaps of MYC and Omomyc levels around TSSs of all MYC promoter-target genes in BT168FO (A) cells, treated or not with Dox for 24 h. TSS regions are ranked by decreasing MYC occupancy in untreated cells. Each row shows the &#177; 5 kb region centred on TSSs. Colour scaled intensities are in units of tags per 50bp. The plots adjacent to each heatmap depict MYC and Omomyc binding patterns at genes in the two gene clusters denoted by arrows, in cells treated or not with Dox.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_3-B</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 3-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B</infon>
    <passage>
      <offset>0</offset>
      <text>A-B Seqminer heatmaps of MYC and Omomyc levels around TSSs of all MYC promoter-target genes in U87FO (B) cells, treated or not with Dox for 24 h. TSS regions are ranked by decreasing MYC occupancy in untreated cells. Each row shows the &#177; 5 kb region centred on TSSs. Colour scaled intensities are in units of tags per 50bp. The plots adjacent to each heatmap depict MYC and Omomyc binding patterns at genes in the two gene clusters denoted by arrows, in cells treated or not with Dox.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_4-A</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 4-A</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A</infon>
    <passage>
      <offset>0</offset>
      <text>A Heatmap of RNA Pol II levels around TSSs of MYC promoter-target genes in BT168FO cells, treated or not with Dox for 24 h. TSS regions are ranked by decreasing MYC occupancy in untreated cells. Each row shows the &#177; 5 kb region centred on TSSs. Colour scaled intensities are in tags/50bp.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_4-B</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 4-B</infon>
    <infon key="sourcedata_figure_dir">Figure_4-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Tracks of Pol II binding signals (ChIP-seq) at NCL, miR-17-92, OLIG2, HDAC1, and DUSP10 genes in BT168FO cells treated or not with Dox for 24 h. The y-axis shows Pol II binding signals as tags/500bp/million reads. The x-axis displays genomic positions; introns as lines, exons as boxes. Arrowheads denote direction of transcription. Blue and green bars denote the presence of MYC or Omomyc peaks. Grey boxes are TSS regions.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_4-C</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 4-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C</infon>
    <passage>
      <offset>0</offset>
      <text>C Transcript levels (FPKM from RNA-seq data) in BT168FO cells of the genes shown in B. Data are means of 3 independent biological replicates.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_4-D</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 4-D</infon>
    <infon key="sourcedata_figure_dir">Figure_4-D</infon>
    <passage>
      <offset>0</offset>
      <text>D Ratio between fold enrichments (specific antibody / IgG signal) derived from qChIPs of Pol II-Ser2p and Pol II-Ser5p (n = 3; mean &#177; SD).</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_4-E</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 4-E</infon>
    <infon key="sourcedata_figure_dir">Figure_4-E</infon>
    <passage>
      <offset>0</offset>
      <text>E RNA Polymerase II traveling ratio distribution from the Pol II ChIP-seqs, in the presence or absence of Dox.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_5-A</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 5-A</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A</infon>
    <passage>
      <offset>0</offset>
      <text>A Promoter occupancy by MYC correlates with transcript levels in cells untreated with doxycycline (black line). In doxycycline treated cells promoter occupancy by MYC is lower, and no longer increases together with transcript levels. The scatter plot displays MYCChIP-seq reads at promoters (-1000, +100 regions with respect to TSS) in BT168FO cells - untreated (black) or upon 48 h Dox treatment (blue) - versus transcript levels (FPKM from RNA-seq data).</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_5-B</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 5-B</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Distribution of transcript level differences (&#916; FPKM) of single genes classified as promoter-targets (green), intragenic-targets (blue), intergenic-targets (red) in Dox treated (24 h) versus untreated cells, plotted against expression in untreated cells (n=3). &#916; FPKM = FPKM_24h Dox - FPKM_no Dox.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_5-C</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 5-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-C</infon>
    <passage>
      <offset>0</offset>
      <text>C The table first row shows the number of genes significantly up or down regulated at 24 h of Dox treatment, subdivided in promoter-, intragenic-, intergenic-targets (&#177; 50 kbp from TSS), and the rest. The following rows depict - for each gene class - mean (average) values of FPKM in cells treated or not with Dox for 24 h and the corresponding &#916; FPKM and Fold change (Fc). Data are from 3 independent biological replicates.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_5-D</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 5-D</infon>
    <infon key="sourcedata_figure_dir">Figure_5-D</infon>
    <passage>
      <offset>0</offset>
      <text>D Transcript level distribution of MYC promoter-targets significantly down (red dots) or up (green dots) modulated in cells treated with Dox for 24 h vs. untreated cells. Transcript levels, expressed as FPKM, represent averages of three independent experiments.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_6-A</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 6-A</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A</infon>
    <passage>
      <offset>0</offset>
      <text>A RNA-seq expression values of select genes in BT168FO GSCs along a 48 h time course of Omomyc induction (n = 3 independent biological replicates). The block on the left represents DUSP (dual specificity phosphatase) family genes. The middle block contains transcription factors (TFs): the upper thirteen (ASCL1-SALL1) are GSC-specific and the remaining ones are oncogenic. The right block contains genes, including well-known MYC targets, with functions in proliferation, neurodifferentiation, and gliomagenesis. The first column of each block represents the average expression (log2 FPKM) in untreated cells (0 h) in the colour scale illustrated by the lower bar: violet indicates low and blue high expression. The other columns depict relative expression versus untreated cells (average log2 FC) at different times (8-48h) of Dox treatment, according to the scale shown by the upper bar: red indicating low and green high expression. The table in the upper left summarizes the GSEA score of the set 19 GSC-specific transcription factors [40], showing a significant downregulation by Omomyc.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_6-B</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 6-B</infon>
    <infon key="sourcedata_figure_dir">Figure_6-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Enrichment plots obtained by GSEA (Gene Set Enrichment Analysis) of RNA-seq data from BT168FO cells. Left: genes downregulated by Omomyc in BT168FO identify the set of genes targeted by the GSC core TFs [40]. Middle: Omomyc downregulated genes identify a gene set upregulated by MYC in cancer cells [66]. Right: genes upregulated by Omomyc identify genes downregulated in small cell lung cancers carrying MYC amplification [2]. .</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_7-B</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 7-B</infon>
    <infon key="sourcedata_figure_dir">Figure_7-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Immunoblots of EGFR, ZEB1 and GAPDH loading control expression in BT168FO and BT275FO after 2 days with (+) or without (-) Dox. Representative images are shown.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_7-C</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 7-C</infon>
    <infon key="sourcedata_figure_dir">Figure_7-C</infon>
    <passage>
      <offset>0</offset>
      <text>C RT-qPCR expression analysis of selected miRs in U87FO cells grown 48 h in the presence (+) or absence (-) of Dox (n = 3; mean &#177; SD). Expression levels were normalized using U6RNA as control. Expression levels in non-induced cells were set as 1.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_7-D</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 7-D</infon>
    <infon key="sourcedata_figure_dir">Figure_7-D</infon>
    <passage>
      <offset>0</offset>
      <text>D EGFR, ZEB1, and GAPDH immunoblots in the same cells as in panel C. Representative images are shown.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_7-E</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 7-E</infon>
    <infon key="sourcedata_figure_dir">Figure_7-E</infon>
    <passage>
      <offset>0</offset>
      <text>E EGFR, ZEB1, and GAPDHimmunoblots in uninduced U87FO cells (-) and in cells transfected with LNA oligos targeting miR-200a-200b-429 (LNA 200) and miR-146b (LNA 146b), or with a non-targeting LNA (C), and induced with Dox for 48 h (+Dox). Representative images are shown.</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_7-F</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 7-F</infon>
    <infon key="sourcedata_figure_dir">Figure_7-F</infon>
    <passage>
      <offset>0</offset>
      <text>F MTS cell proliferation assay of uninduced or Dox induced U87FO cells, transfected with either a non-targeting LNA (LNA C), or LNA oligos targeting the miR-200a-200b-429 cluster (LNA 200), miR-146b (LNA 146b), or both (LNAmix) and analysed at 24, 48 and 72h (n = 3; mean &#177; SD).</text>
    </passage>
  </document>
  <document>
    <id>5283599 Figure_7-G</id>
    <infon key="sourcedata_document">2444</infon>
    <infon key="doi">10.15252/embr.201541489</infon>
    <infon key="pmc_id">5283599</infon>
    <infon key="figure">Figure 7-G</infon>
    <infon key="sourcedata_figure_dir">Figure_7-G</infon>
    <passage>
      <offset>0</offset>
      <text>G Migration assay of U87FO cells transfected with non-targeting control LNA oligos (LNA C) or with LNA oligos targeting miR-200a-200b-429 (LNA 200); cells were either untreated (-) or treated with Dox for 24 h (+Dox); (n = 3; mean &#177; SD).</text>
    </passage>
  </document>
</collection>
